Objective To investigate the influence of Raltitrexed combined with Bevacizumab for tumor markers and matrix metalloproteinases of patients with advanced colorectal cancer.Methods A total of 92 patients with advanced colorectal cancer in Liaoyang City Central Hospital from February 2020 to October 2022 were selected as the study object,and they were divided into control group(46 cases)and observation group(46 cases)according to random number table method.The control group was treated with Capecitabine combined with Bevacizumab,and the observation group was treated with Raltitrexed combined with Bevacizumab.Then the clinical effective rates,disease control rates,adverse reactions rates,tumor markers(carcinoembryonic antigen[CEA],carbohydrate antigen 19-9[CA19-9],carbohydrate antigen 125[CA125]and carbohydrate antigen 72-4[CA72-4])and matrix metalloproteinases(matrix metalloproteinase-2[MMP-2],matrix metalloproteinase-9[MMP-9]and tissue inhibitor of metalloproteinase[TIMP-1])before and after the treatment of two groups were compared.Results The clinical effective rate and disease control rate of observation group were higher than those of control group,the adverse reactions rates were significantly lower than those of control group,and the differences were statistically significant(P＜0.05).The tumor markers and matrix metalloproteinases of two groups before the treatment were compared,and the differences were not statistically significant(P＞0.05).The tumor markers and matrix metallopro-teinases of two groups at second and forth cycles after the treatment were lower than those before the treatment,and the two items of observation group were all lower than those of control group,and the differences were statistically significant(P＜0.05).Conclusion The effect of Raltitrexed combined with Bevacizumab in patients with advanced colorectal cancer is bet-ter,its safety is higher,and it can effectively control the expression of tumor markers and matrix metalloproteinases of patients,so its application value in patients with advanced colorectal cancer is higher.
维普
万方数据